Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $20.40

Keros Therapeutics, Inc. (NASDAQ:KROS) has been given a consensus recommendation of “Hold” by the eight brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $20.40.

A number of brokerages have weighed in on KROS. Wall Street Zen cut shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Weiss Ratings lowered shares of Keros Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Friday, May 15th.

Insider Buying and Selling at Keros Therapeutics

In other Keros Therapeutics news, Director Nima Farzan sold 2,625 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the sale, the director owned 9,767 shares of the company’s stock, valued at $104,799.91. The trade was a 21.18% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Julius Knowles sold 2,625 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $10.73, for a total value of $28,166.25. Following the transaction, the director owned 10,958 shares of the company’s stock, valued at approximately $117,579.34. This represents a 19.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 8,425 shares of company stock valued at $89,994 over the last quarter. 12.60% of the stock is owned by company insiders.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Financial Management Professionals Inc. acquired a new position in Keros Therapeutics in the 4th quarter valued at about $29,000. Caitong International Asset Management Co. Ltd lifted its position in shares of Keros Therapeutics by 254.6% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock worth $33,000 after purchasing an additional 1,166 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Keros Therapeutics by 149.2% in the second quarter. Tower Research Capital LLC TRC now owns 3,153 shares of the company’s stock valued at $42,000 after purchasing an additional 1,888 shares during the period. Lazard Asset Management LLC purchased a new position in shares of Keros Therapeutics in the first quarter valued at approximately $129,000. Finally, New York State Common Retirement Fund grew its holdings in shares of Keros Therapeutics by 264.1% in the second quarter. New York State Common Retirement Fund now owns 10,616 shares of the company’s stock valued at $142,000 after purchasing an additional 7,700 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Keros Therapeutics Trading Up 0.3%

Shares of NASDAQ:KROS opened at $10.64 on Thursday. The business has a 50-day moving average price of $10.87 and a 200 day moving average price of $13.33. The company has a market capitalization of $210.59 million, a price-to-earnings ratio of -3.53 and a beta of 0.97. Keros Therapeutics has a 12-month low of $9.69 and a 12-month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.19). Keros Therapeutics had a negative net margin of 256.60% and a negative return on equity of 17.04%. The company had revenue of $0.37 million during the quarter, compared to analysts’ expectations of $1.93 million. As a group, equities research analysts predict that Keros Therapeutics will post -5.19 earnings per share for the current fiscal year.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.